# VirnetX Holding Corp: financial statements, quarterly

VHC · Nasdaq · CIK 1082324 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vhc.md) · [Financials](/companies/vhc/financials.md) · [Filings](/companies/vhc/filings.md) · [Insiders](/companies/vhc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vhc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [3.0](/filings/0001140361-24-046446.md) | [0.0 d](/filings/0001140361-25-009024.md) | [2.0](/filings/0001140361-25-018930.md) | [1.0](/filings/0001140361-25-030577.md) | [2.0](/filings/0001140361-25-042294.md) | [0.0 d](/filings/0001140361-26-010895.md) | [0.0](/filings/0001140361-26-021650.md) | [48.0](/filings/0001140361-26-033140.md) | [58.0](/filings/0001140361-25-042294.md) | [56.0 d](/filings/0001140361-26-010895.md) | [0.0](/filings/0001140361-26-021650.md) | [0.0](/filings/0001140361-26-033140.md) |
| Research and development | $k | [1,218](/filings/0001140361-24-046446.md) | [2,372 d](/filings/0001140361-25-009024.md) | [1,268](/filings/0001140361-25-018930.md) | [1,223](/filings/0001140361-25-030577.md) | [1,176](/filings/0001140361-25-042294.md) | [2,371 d](/filings/0001140361-26-010895.md) | [1,259](/filings/0001140361-26-021650.md) | [1,215](/filings/0001140361-26-033140.md) | [1,143](/filings/0001140361-25-042294.md) | [2,037 d](/filings/0001140361-26-010895.md) | [1,162](/filings/0001140361-26-021650.md) | [1,126](/filings/0001140361-26-033140.md) |
| Selling, general and administrative | $k | [4,420](/filings/0001140361-24-046446.md) | [5,406 d](/filings/0001140361-25-009024.md) | [3,660](/filings/0001140361-25-018930.md) | [3,193](/filings/0001140361-25-030577.md) | [3,213](/filings/0001140361-25-042294.md) | [4,298 d](/filings/0001140361-26-010895.md) | [2,788](/filings/0001140361-26-021650.md) | [2,777](/filings/0001140361-26-033140.md) | [3,059](/filings/0001140361-25-042294.md) | [4,824 d](/filings/0001140361-26-010895.md) | [3,346](/filings/0001140361-26-021650.md) | [3,526](/filings/0001140361-26-033140.md) |
| Operating income | $k | [(5,635)](/filings/0001140361-24-046446.md) | [(7,778) d](/filings/0001140361-25-009024.md) | [(4,926)](/filings/0001140361-25-018930.md) | [(4,415)](/filings/0001140361-25-030577.md) | [(4,387)](/filings/0001140361-25-042294.md) | [(6,669) d](/filings/0001140361-26-010895.md) | [(4,047)](/filings/0001140361-26-021650.md) | [(3,944)](/filings/0001140361-26-033140.md) | [(4,644)](/filings/0001140361-25-042294.md) | [(6,805) d](/filings/0001140361-26-010895.md) | [(4,508)](/filings/0001140361-26-021650.md) | [(4,652)](/filings/0001140361-26-033140.md) |
| Income tax | $k | [(1.0)](/filings/0001140361-24-046446.md) | [0.0 d](/filings/0001140361-25-009024.md) | [0.0](/filings/0001140361-25-018930.md) | [3.0](/filings/0001140361-25-030577.md) | [0.0](/filings/0001140361-25-042294.md) | [0.0 d](/filings/0001140361-26-010895.md) | [2.0](/filings/0001140361-26-021650.md) | [0.0](/filings/0001140361-26-033140.md) | [0.0](/filings/0001140361-25-042294.md) | [(4.0) d](/filings/0001140361-26-010895.md) | [0.0](/filings/0001140361-26-021650.md) | [0.0](/filings/0001140361-26-033140.md) |
| Net income | $k | [(4,918)](/filings/0001140361-24-046446.md) | [(7,107) d](/filings/0001140361-25-009024.md) | [(4,291)](/filings/0001140361-25-018930.md) | [(3,830)](/filings/0001140361-25-030577.md) | [(3,839)](/filings/0001140361-25-042294.md) | [(6,215) d](/filings/0001140361-26-010895.md) | [(3,679)](/filings/0001140361-26-021650.md) | [(3,621)](/filings/0001140361-26-033140.md) | [(4,348)](/filings/0001140361-25-042294.md) | [(6,577) d](/filings/0001140361-26-010895.md) | [(4,354)](/filings/0001140361-26-021650.md) | [(4,527)](/filings/0001140361-26-033140.md) |
| Diluted EPS | $ per share | [(1.36)](/filings/0001140361-24-046446.md) | not reported | [(1.19)](/filings/0001140361-25-018930.md) | [(1.07)](/filings/0001140361-25-030577.md) | [(1.07)](/filings/0001140361-25-042294.md) | not reported | [(1.01)](/filings/0001140361-26-021650.md) | [(0.99)](/filings/0001140361-26-033140.md) | [(1.18)](/filings/0001140361-25-042294.md) | not reported | [(1.16)](/filings/0001140361-26-021650.md) | [(1.20)](/filings/0001140361-26-033140.md) |
| Basic EPS | $ per share | [(1.36)](/filings/0001140361-24-046446.md) | not reported | [(1.19)](/filings/0001140361-25-018930.md) | [(1.07)](/filings/0001140361-25-030577.md) | [(1.07)](/filings/0001140361-25-042294.md) | not reported | [(1.01)](/filings/0001140361-26-021650.md) | [(0.99)](/filings/0001140361-26-033140.md) | [(1.18)](/filings/0001140361-25-042294.md) | not reported | [(1.16)](/filings/0001140361-26-021650.md) | [(1.20)](/filings/0001140361-26-033140.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [27.8](/filings/0001140361-23-052446.md) | [26.3](/filings/0001140361-25-009024.md) | [27.6](/filings/0001140361-24-026230.md) | [26.3](/filings/0001140361-24-037312.md) | [25.1](/filings/0001140361-24-046446.md) | [23.3](/filings/0001140361-26-010895.md) | [23.2](/filings/0001140361-25-018930.md) | [17.3](/filings/0001140361-25-030577.md) | [17.1](/filings/0001140361-25-042294.md) | [15.5](/filings/0001140361-26-033140.md) | [14.8](/filings/0001140361-26-021650.md) | [13.1](/filings/0001140361-26-033140.md) |
| Current assets | $m | [61.5](/filings/0001140361-23-052446.md) | [53.8](/filings/0001140361-25-009024.md) | [50.4](/filings/0001140361-24-026230.md) | [47.2](/filings/0001140361-24-037312.md) | [44.0](/filings/0001140361-24-046446.md) | [38.2](/filings/0001140361-26-010895.md) | [34.6](/filings/0001140361-25-018930.md) | [31.5](/filings/0001140361-25-030577.md) | [28.4](/filings/0001140361-25-042294.md) | [21.7](/filings/0001140361-26-033140.md) | [17.6](/filings/0001140361-26-021650.md) | [14.1](/filings/0001140361-26-033140.md) |
| Total assets | $m | [63.9](/filings/0001140361-23-052446.md) | [60.4](/filings/0001140361-25-009024.md) | [62.3](/filings/0001140361-24-026230.md) | [58.9](/filings/0001140361-24-037312.md) | [55.6](/filings/0001140361-24-046446.md) | [49.6](/filings/0001140361-26-010895.md) | [45.1](/filings/0001140361-25-018930.md) | [41.8](/filings/0001140361-25-030577.md) | [38.0](/filings/0001140361-25-042294.md) | [31.1](/filings/0001140361-26-033140.md) | [26.7](/filings/0001140361-26-021650.md) | [23.0](/filings/0001140361-26-033140.md) |
| Current liabilities | $m | [1.6](/filings/0001140361-23-052446.md) | [1.3](/filings/0001140361-25-009024.md) | [7.0](/filings/0001140361-24-026230.md) | [7.0](/filings/0001140361-24-037312.md) | [7.1](/filings/0001140361-24-046446.md) | [7.2](/filings/0001140361-26-010895.md) | [2.0](/filings/0001140361-25-018930.md) | [1.9](/filings/0001140361-25-030577.md) | [2.1](/filings/0001140361-25-042294.md) | [2.0](/filings/0001140361-26-033140.md) | [2.1](/filings/0001140361-26-021650.md) | [2.3](/filings/0001140361-26-033140.md) |
| Total liabilities | $m | [1.6](/filings/0001140361-23-052446.md) | [4.4](/filings/0001140361-25-009024.md) | [10.1](/filings/0001140361-24-026230.md) | [10.1](/filings/0001140361-24-037312.md) | [10.1](/filings/0001140361-24-046446.md) | [10.0](/filings/0001140361-26-010895.md) | [8.7](/filings/0001140361-25-018930.md) | [8.6](/filings/0001140361-25-030577.md) | [8.7](/filings/0001140361-25-042294.md) | [8.6](/filings/0001140361-26-033140.md) | [7.8](/filings/0001140361-26-021650.md) | [7.9](/filings/0001140361-26-033140.md) |
| Shareholders' equity | $m | [62.3](/filings/0001140361-24-046446.md) | [56.0](/filings/0001140361-26-010895.md) | [52.2](/filings/0001140361-25-030577.md) | [48.8](/filings/0001140361-25-042294.md) | [45.5](/filings/0001140361-25-042294.md) | [39.6](/filings/0001140361-26-033140.md) | [36.4](/filings/0001140361-26-033140.md) | [33.2](/filings/0001140361-26-033140.md) | [29.3](/filings/0001140361-25-042294.md) | [22.5](/filings/0001140361-26-033140.md) | [18.9](/filings/0001140361-26-033140.md) | [15.1](/filings/0001140361-26-033140.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(3,291) d](/filings/0001140361-24-046446.md) | [(7,016) d](/filings/0001140361-25-009024.md) | [(3,516)](/filings/0001140361-25-018930.md) | [(3,080) d](/filings/0001140361-25-030577.md) | [(3,221) d](/filings/0001140361-25-042294.md) | [(5,510) d](/filings/0001140361-26-010895.md) | [(3,894)](/filings/0001140361-26-021650.md) | [(2,938) d](/filings/0001140361-26-033140.md) | [(3,004) d](/filings/0001140361-25-042294.md) | [(5,808) d](/filings/0001140361-26-010895.md) | [(4,297)](/filings/0001140361-26-021650.md) | [(3,320) d](/filings/0001140361-26-033140.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001140361-24-046446.md) | [65.0 d](/filings/0001140361-25-009024.md) | not reported | not reported | [0.0 d](/filings/0001140361-25-042294.md) | [11.0 d](/filings/0001140361-26-010895.md) | not reported | not reported | [17.0 d](/filings/0001140361-25-042294.md) | [0.0 d](/filings/0001140361-26-010895.md) | not reported | not reported |
| Dividends paid | $k | [0.0 d](/filings/0001140361-24-046446.md) | [0.0 d](/filings/0001140361-25-009024.md) | not reported | not reported | [0.0 d](/filings/0001140361-24-046446.md) | [0.0 d](/filings/0001140361-25-009024.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [3,571](/filings/0001140361-23-052446.md) | [3,571](/filings/0001140361-24-026230.md) | [3,573](/filings/0001140361-24-037312.md) | [3,612](/filings/0001140361-24-046446.md) | [3,616](/filings/0001140361-25-018930.md) | [3,593](/filings/0001140361-25-030577.md) | [3,603](/filings/0001140361-25-042294.md) | [3,627](/filings/0001140361-26-021650.md) | [3,660](/filings/0001140361-26-033140.md) | [3,673](/filings/0001140361-25-042294.md) | [3,754](/filings/0001140361-26-021650.md) | [3,770](/filings/0001140361-26-033140.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,216,633 at 2026-08-07, from the cover of the [10-Q filed 2026-08-14](/filings/0001140361-26-033140.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.